Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study

Kim, J.-M.; Stewart, Robert; Bae, Kyung‐Yeol; Kang, Hyun-Kyu; Kim, Saeryun; Shin, Il‐Seon; Hong, Young Joon; Ahn, Youngkeun; Yoon, Jin‐Sang

doi:10.1017/s003329171400275x

Cited by 19 publications

(23 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Depression was significantly associated with worse quality of life (QoL) even in patients with recently developed ACS. Depression treatment with escitalopram was associated with significant QoL improvement over the 24‐week treatment period, the effect of which extended to 1 year …”

Section: Treatment Considerationsmentioning

confidence: 99%

“…Depression treatment with escitalopram was associated with significant QoL improvement over the 24-week treatment period, the effect of which extended to 1 year. 60 Using a U.K. general-practice research database, 1651 cases of upper gastrointestinal (GI) bleeding and 248 cases of ulcer perforation were found between April 1993 and September 1997 among patients aged 40-70 years and 10,000 matched controls. Exposure to SSRIs was observed in 3.1% of patients with GI bleeding but in only 1% of controls, with an adjusted RR = 3 (95% CI, 2.1-4.4).…”

Section: Treatment Considerationsmentioning

confidence: 99%

See 1 more Smart Citation

The interface of depression and cardiovascular disease: therapeutic implications

Seligman

Nemeroff

2015

Annals of the New York Academy of Sciences

119

View full text Add to dashboard Cite

Patients with major depression are at an increased risk for developing cardiovascular disease, respond more poorly to treatment, and exhibit worse outcomes, including increased morbidity and mortality. This article reviews the relationship between depression and heart disease, with an emphasis on epidemiology, biological substrates that likely underlie this relationship, and implications for treatment.

show abstract

Section: Treatment Considerationsmentioning

confidence: 99%

Section: Treatment Considerationsmentioning

confidence: 99%

The interface of depression and cardiovascular disease: therapeutic implications

Seligman

Nemeroff

2015

Annals of the New York Academy of Sciences

119

View full text Add to dashboard Cite

show abstract

“…In patients with ACS, comorbid depression is associated with poorer quality of life [82]. Therefore, given that CC has a better effect than CAU on depression, the fact that depression treatment in ACS has a known favourable prognostic effect on cardiac outcomes [83], and the fact that CC has a positive effect on physical outcomes, CC should be considered a good treatment option in ACS.…”

Section: Summary Of Evidencementioning

confidence: 99%

“…Although more procedures make CC more costly, several studies have shown that CC improves quality of life for 14 acceptable additional costs [38,75]. This has been shown to be the case for depression comorbid with various chronic medical conditions [76][77][78][79][80][81].In patients with ACS, comorbid depression is associated with poorer quality of life [82]. Therefore, given that CC has a better effect than CAU on depression, the fact that depression treatment in ACS has a known favourable prognostic effect on cardiac outcomes [83], and the fact that CC has a positive effect on physical outcomes, CC should be considered a good treatment option in ACS.…”

mentioning

confidence: 99%

Illness burden and physical outcomes associated with collaborative care in patients with comorbid depressive disorder in chronic medical conditions: A systematic review and meta-analysis

Sluijs

Castelijns

Eijsbroek

et al. 2018

General Hospital Psychiatry

View full text Add to dashboard Cite

Objective Collaborative care (CC) improves depressive symptoms in people with comorbid depressive disorder in chronic medical conditions, but its effect on physical symptoms has not yet systematically been reviewed. This study aims to do so. Methods Systematic review and meta-analysis was conducted using Pubmed, the Cochrane Library, and the European and US Clinical Trial Registers. Eligible studies included randomized controlled trials (RCTs) of CC compared to care as usual (CAU), in primary care and general hospital setting, reporting on physical and depressive symptoms as outcomes. Overall treatment effects were estimated for illness burden, physical outcomes and depression, respectively. Results Twenty RCTs were included, with N = 4774 patients. The overall effect size of CC versus CAU for illness burden was OR 1.64 (95%CI 1.47;1.83), d = 0.27 (95%CI 0.21;0.33). Overall, depression outcomes were better for CC than for CAU. Moderator analyses did not yield statistically significant differences. Conclusions CC is more effective than CAU in terms of illness burden, physical outcomes and depression, in patients with comorbid depression in chronic medical conditions. More research covering multiple physical disorders is needed. Corresponding AuthorChristina Van der Feltz-Cornelis Corresponding Author's InstitutionClinical Centre of excellence for Body, Mind and Health, GGz Breburg, Tilburg, The Netherlands Appendix A_searchterm.docx [Figure] Appendix B_PRISMA 2009 checklist.docx [Figure] Appendix C_risk of bias assessment.docx [Figure] Forest plot 1.docx [Figure] Forest plot 2.docx [Figure] Forest plot 3.docx [Figure] Forest plot 4.docx [Figure] Forest plot 5.docx [Figure] Funnel plot 1.docx [Figure] PRISMA flow diagram.docx [Figure] Table] To view all the submission files, including those not included in the PDF, click on the manuscript title on your EVISE Homepage, then click 'Download zip file'. Order of AuthorsDear Dr. Huffman,We have received your comments with regard to our manuscript 'Physical outcomes of collaborative care and illness burden in patients with comorbid depressive disorder in chronic medical conditions: a systematic review and meta-analysis' (GHP_2017_110_R1).We would like to thank you for the fast and careful review of our manuscript, and are pleased that your Journal is interested in considering a revised version. We have carefully attended to the remarks, which were most helpful for improving the manuscript. Enclosed you will also find the revised version of the manuscript, in which we have marked the revisions in yellow.During the revision process we have also changed the title to: 'Illness burden and physical outcomes associated with collaborative care in patients with comorbid depressive disorder in chronic medical conditions: A systematic review and meta-analysis'. We hope that our revised manuscript is suitable for publication in General Hospital Psychiatry. Editor comments and our response:Thank you very much for your comprehensive re...

show abstract

“…It has been also shown that escitalopram can reduce the risk of post-ACS depression and improve quality of life among patients with ACS and depression (64,65). However, there is a possibility of SSRI increasing the risk of bleeding events, especially if used concurrently with nonsteroidal anti-inflammatory drugs or aspirin (9,66).…”

Section: Pharmacotherapymentioning

confidence: 99%

A Narrative Review of the Relationship Between Coronary Heart Disease and Anxiety

Dahale

Menon

Jaisoorya

2017

Iran J Psychiatry Behav Sci

View full text Add to dashboard Cite

Context: Coronary heart disease (CHD) is the most common cause of death and disability in the world. While the relationship between depression and CHD is well documented, anxiety remains understudied, despite its common cooccurrence. Evidence Acquisition: A PubMed (MEDLINE) search was conducted in order to find articles published between January 2000 and December 2015, using the following keywords: "coronary heart disease" and "anxiety". In total, 79 out of 1138 articles were considered relevant by consensus between the authors and were reviewed. Results: According to previous studies, anxiety is suggested to increase the risk of CHD. Anxiety is associated with an increase in cardiac complications, morbidity and mortality. Also, a lower quality of life has been described among patients after acute coronary syndrome, with a few studies reporting contradictory findings. Although studies on anxiety management in CHD are sparse, selective serotonin reuptake inhibitors have been shown to be relatively safe for patients. On the other hand, psychological interventions have not been adequately evaluated, although some studies have revealed their advantages. Conclusions: Evidence suggests that anxiety is associated with the development and course of CHD. Awareness and appropriate training in cardiology settings need to be prioritized to improve early identification and initiation of effective management.

show abstract

Effects of depression co-morbidity and treatment on quality of life in patients with acute coronary syndrome: the Korean depression in ACS (K-DEPACS) and the escitalopram for depression in ACS (EsDEPACS) study

Abstract: Depression was significantly associated with worse QoL even in patients with recently developed ACS. Depression treatment was associated with QoL improvement in ACS patients in the 24-week treatment period, the effects of which extended to 1 year.

Cited by 19 publications

References 40 publications

The interface of depression and cardiovascular disease: therapeutic implications

The interface of depression and cardiovascular disease: therapeutic implications

Illness burden and physical outcomes associated with collaborative care in patients with comorbid depressive disorder in chronic medical conditions: A systematic review and meta-analysis

A Narrative Review of the Relationship Between Coronary Heart Disease and Anxiety

Contact Info

Product

Resources

About